Should You Buy Pfizer Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pfizer Inc. (PFE) is rated as a strong fundamental performer with a QOC score of 7.5/10. Trading at $27.55, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 9 of 12 CirclFi valuation models project upside for Pfizer Inc. (PFE) at $27.55 — the model consensus leans bullish, with a Quality Score of 7.5/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Pfizer Inc. (PFE) in 2026?
What Is the Bull Case vs the Bear Case for Pfizer Inc. (PFE)?
| Bull case — $47.01 target (+70.6%) | Bear case — $20.06 target (-27.2%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Pfizer Inc.'s rating of 7.5/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $20.06 (-27.2%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, 9 of 12 models identify upside from $27.55 to a median fair value of $35.64, indicating the market hasn't fully priced in Pfizer Inc.'s earnings power. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +97.8% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $47.01 (+70.6%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | Industry headwind: patent expiration revenue loss represents a meaningful risk for Pfizer Inc. and its Drug Manufacturers - General peers. |
| Industry tailwind: orphan drug designation could provide meaningful support for Pfizer Inc.'s revenue and margin trajectory in the Drug Manufacturers - General space. | |
| The company's $157.0B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does PFE Compare to Its Drug Manufacturers - General Peers?
Valuation data pages: SNY · OGN · ABBV · GRFS · BIIB · AMRN · MIRA · MRK · GSK · GILD
Which Other Stocks Score Like PFE on Quality?
Closest companies to PFE’s Quality of Company score of 7.5/10, across all industries.
- ARKO — Arko Corp. (QOC 7.5) · analysis
- GTY — Getty Realty Corp. (QOC 7.5) · analysis
- JAKK — JAKKS Pacific, Inc. (QOC 7.5) · analysis
- MMM — 3M Company (QOC 7.5) · analysis
- BDTX — Black Diamond Therapeutics, Inc. (QOC 7.5) · analysis
- ICUI — ICU Medical, Inc. (QOC 7.5) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Pfizer Inc. (PFE) Worth Buying in 2026?
Pfizer Inc. at $27.55 presents what our engine identifies as a high-conviction opportunity: 9 of 12 models see upside, quality stands at 7.5/10, and the median fair value of $35.64 implies +29.4% return potential. Investors should verify this thesis against their own risk parameters and time horizon.
These are quantitative model outputs, not investment recommendations. Pfizer Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About PFE Stock?
Should I buy PFE stock right now?
Based on CirclFi's multi-model analysis, 9 of 12 models see upside for PFE at $27.55. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Pfizer Inc.?
Key risks include: wide model disagreement (134% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - General companies. Always diversify and consult a financial advisor.
How does PFE compare to its competitors?
Among Drug Manufacturers - General peers, PFE holds a Quality Score of 7.5/10. Comparable companies include SNY (QOC 7.6), OGN (QOC 7.3), ABBV (QOC 7.6). The relative ranking helps investors identify whether PFE offers better fundamental quality than alternatives in the same sector.
Is PFE a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. PFE's Quality Score of 7.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy PFE at?
CirclFi does not provide target buy prices or price alerts. However, our 12 active models produce fair value estimates ranging from $20.06 to $47.01. At $27.55, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for PFE.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad